Equities

Profile data is unavailable for this security.

About the company

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The Pharmaceuticals division also comprises the radiology business. The Consumer Health segment is engaged in the development, production and marketing of mainly nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products. The Covestro segment is engaged in the development, production and marketing of raw materials for polyurethanes, polycarbonate granules and sheets and raw materials for coatings, adhesives.

  • Revenue in EUR (TTM)48.52bn
  • Net income in EUR4.54bn
  • Incorporated--
  • Employees115.68k
  • Location
    Bayer AGKaiser-Wilhelm-Allee 1LEVERKUSEN 51373GermanyDEU
  • Phone+49 214301
  • Fax+49 2 143066328
  • Websitehttps://www.bayer.de/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BAYX.N:GER since
announced
Transaction
value
Boehringer Ingelheim Vetmedica Inc-Cydectin Product PortfolioAnnounced07 Dec 201607 Dec 2016Announced35.66%--
Data delayed at least 15 minutes, as of Oct 16 2017 16:35 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Alexion Pharmaceuticals, Inc.3.41bn521.77m31.43bn3.12k61.033.5534.019.212.312.3115.0739.620.25730.78775.171,093,190.003.945.594.176.1591.4690.9515.2916.102.7811.460.25080.0018.4331.53176.3417.8872.22--
Bayer AG48.52bn4.54bn98.90bn115.68k22.633.0312.292.045.295.7656.7539.480.61372.464.07421,171.906.505.598.697.4257.3653.3710.588.201.296.650.351255.031.485.075.9111.539.8010.35
Roche Holding Ltd.51.90bn9.68bn210.70bn94.05k21.659.1115.254.0611.2511.2560.3826.740.70921.905.67551,801.1013.4514.2020.4621.0670.7872.2918.9720.700.919832.830.455170.365.053.538.040.493918.473.82
Novartis AG47.96bn6.38bn221.35bn119.00k31.662.9118.194.622.672.6720.0729.110.37092.515.79405,102.904.926.846.148.5165.4166.9513.2716.360.751--0.30474.63-1.93-3.62-4.35-5.933.822.45
Chugai Pharmaceutical Co Ltd497.02bn58.14bn2.90tn7.25k48.854.25--5.84106.25106.25908.341,221.410.62581.353.4468,602,340.007.417.568.658.9350.8453.0811.8511.833.32796.750.000650.46-1.425.66-12.328.7526.515.39
Astellas Pharma Inc1.30tn194.56bn3.04tn17.20k15.832.3011.752.3492.6892.68618.30639.150.72132.013.8575,368,220.0010.828.6913.9111.1474.6873.1015.0112.091.76--0.027844.52-4.456.2312.9122.83-5.386.34
Takeda Pharmaceutical Co Ltd1.75tn160.20bn4.91tn29.90k30.492.4112.762.81203.74203.742,228.442,580.100.42792.284.0158,404,180.003.921.535.071.9768.8470.019.173.691.1032.990.375233.39-4.172.8043.38-1.5312.600.00
Data as of Oct 16 2017. Currency figures normalised to Bayer AG's reporting currency: Euro EUR
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.